Management of Refractory Gastritis in a 13-Year-Old
The first critical step is to test for Helicobacter pylori infection, as this is the most common treatable cause of fundal and antral gastritis in children, and if present, requires antibiotic-based eradication therapy rather than continued acid suppression alone.
Diagnostic Workup
The current treatment approach with pantoprazole and levosulpiride is addressing symptoms but not the underlying cause. Here's what needs to happen:
1. Test for H. pylori Immediately
- Perform endoscopy with biopsy if not already done
- Obtain rapid urease test and histology from both antrum and fundus
- If H. pylori is positive, this explains the gastritis and requires eradication therapy
2. If H. pylori is Positive: Eradication Therapy
Based on current AGA guidelines 1, the recommended first-line regimens include:
Bismuth Quadruple Therapy (preferred):
- Bismuth subsalicylate ~300mg four times daily
- Metronidazole 500mg three times daily
- Tetracycline 500mg four times daily (if age-appropriate; typically ≥8 years)
- PPI (pantoprazole 40mg) twice daily
- Duration: 14 days
Alternative: Concomitant Therapy:
- Clarithromycin 500mg twice daily
- Amoxicillin 1g twice daily
- Metronidazole 500mg twice daily
- PPI twice daily
- Duration: 14 days
The evidence shows that successful H. pylori eradication leads to resolution of gastritis within 4-5 weeks 2, 3. In one study, 96.67% of patients achieved H. pylori eradication with pantoprazole-based triple therapy, and 73.33% showed histological improvement from active to stationary chronic gastritis 3.
3. If H. pylori is Negative: Reassess the Diagnosis
Consider:
- Autoimmune gastritis - Check parietal cell antibodies, intrinsic factor antibodies, vitamin B12, and gastrin levels
- Medication-induced gastritis - Review all medications including NSAIDs
- Dietary factors - Assess for excessive spicy foods, caffeine
- Eosinophilic gastritis - Review biopsy for eosinophilic infiltration
Critical Concerns About Current Therapy
Pantoprazole Limitations in Children
The FDA label explicitly states that pantoprazole effectiveness for symptomatic GERD (without erosive esophagitis) has not been established in pediatric patients 4. The drug is only indicated for erosive esophagitis in children ≥5 years. Continuing pantoprazole without documented erosive disease or H. pylori eradication is not evidence-based.
Important safety consideration: A systematic review found that PPIs are not effective in reducing GERD symptoms in infants and lack placebo-controlled efficacy data in older children 5. Furthermore, prolonged PPI use in children is associated with:
- Altered microbiome diversity
- Increased gastrointestinal infections
- Potential bone effects 6
The FDA label warns about fundic gland polyps with long-term use, especially beyond one year 4.
Levosulpiride Considerations
Levosulpiride is a prokinetic that may help with gastric emptying and has been shown to reduce dyspeptic symptoms 7. However, it does not treat the underlying gastritis. Multiple adverse events are reported with prokinetics, including decreased appetite and fatigue 8.
Recommended Management Algorithm
Step 1: Confirm H. pylori status via endoscopy with biopsy (if not done) or non-invasive testing
Step 2A (If H. pylori positive):
- Stop levosulpiride
- Initiate bismuth quadruple therapy or concomitant therapy for 14 days 1
- Confirm eradication 4-6 weeks after completing antibiotics
- Repeat endoscopy at 8-12 weeks to document gastritis resolution
Step 2B (If H. pylori negative):
- Investigate for autoimmune gastritis (antibodies, B12, gastrin)
- Consider stopping PPI if no erosive esophagitis documented
- If symptoms persist, consider H2-receptor antagonist instead
- Dietary modifications and stress management
Step 3 (If first eradication fails):
- Confirm medication adherence
- Consider H. pylori susceptibility testing 1
- Use alternative regimen based on resistance patterns
Common Pitfalls to Avoid
Continuing PPIs indefinitely without addressing H. pylori - This is the most common error. PPIs suppress acid but don't heal H. pylori-induced gastritis 2, 9.
Using PPIs for non-erosive gastritis without H. pylori testing - There are no registered indications for PPI use in chronic non-erosive gastritis without documented erosive disease 10.
Assuming treatment failure means more acid suppression is needed - Refractory symptoms suggest wrong diagnosis or untreated H. pylori, not inadequate acid suppression.
Ignoring the risk of gastric atrophy with long-term PPI use in H. pylori-positive patients - PPIs can accelerate progression to atrophic gastritis and increase gastric cancer risk in H. pylori-infected individuals 11.
The bottom line: Test for H. pylori and treat if positive. If negative, reassess the diagnosis and consider stopping the PPI if there's no documented erosive esophagitis. Continuing the current regimen without addressing the underlying cause will not resolve the gastritis.